January 2023 Top Biopharma Deal: Hutchmed – Takeda for cancer drug fruquintinib
January 2023 Top Biopharma Deal Upfront
Hutchmed development and commercialization deal with Takeda for fruquintinib
Highlighted Deal Financial Comps
Date Announced:
January 23, 2023
Total Deal Value:
$1,130M
Upfront Cash:
$400M
Upfront Equity:
n/a
Option Payments:
n/a
Total Milestones:
$730M dev. and sales milestones
Royalties:
Undisclosed royalties
Cost & Profit Split:
n/a
Deal Synopsis
The Asset:
Hutchmed’s fruquintinib, an oral vascular endothelial growth factor receptors 1/2/3 tyrosine kinase inhibitor (VEGFR 1/2/3)
Deal Structure:
Development and Com License
Partnership Features:
License Hand-Off
Deal Details:
-
Hutchmed granted Takeda exclusive, worldwide rights excluding China, Hong Kong, and Macau to develop and commercialize Hutchmed’s fruquintinib, an oral vascular endothelial growth factor receptors 1/2/3 tyrosine kinase inhibitor for the treatment of refractory metastatic colorectal cancer (CRC).
-
Takeda will be solely responsible for the worldwide development and commercialization of fruquintinib, excluding mainland China, Hong Kong, and Macau.
-
Hutchmed will receive $400M up front and is eligible for up to $730M in development, regulatory, and commercial milestones, plus royalties.
Last Month:
Congrats to Hutchmed and Takeda for landing DealForma’s January 2023 Top Biopharma Deal. Last month’s Deal of the Month was Akeso – Summit for cancer drug ivonescimab. Read about it here.
DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms.
We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.
20,378
Licensing Deals
17,730
Funding Rounds
4,034
M&A
31,012
Company Profiles
5,478
Other Deals
26,505
Drug Sales Figures
All of this by stage, disease indication, modality, target...
More Research by DealForma
Introducing: DealForma plus Tableau
We are excited to introduce DealForma's new Tableau dashboard integration. High quality data on biopharma deals and funding meets interactive charts and visuals. DealForma customers will have exclusive access to the DealForma chart dashboards built on Tableau right...
Venture & IPO – Medtech – Q1 2023
The Medtech sector encompasses medical devices, diagnostics, and digital health solutions, playing a crucial role in healthcare. In Q1 2022, the medtech, devices, digital health therapeutics, and wearables sector experienced a strong opening with 95 funding rounds and...